US firms, particularly companies from the Boston area, continue to dominate Nature Biotechnology's listing of innovative startups, ranked in order of the 10 largest A rounds. This year's list is notable for the proportion of startups focusing on experimental gene therapies; indeed, firms developing adeno-associated virus (AAV) platforms garnered three of last year's largest A rounds. A familiar group of early stage funds participated in most of the financings in Table 1, although the Children's Hospital of Philadelphia's decision to support a startup is notable. In total, the United States accounts for about two-thirds of firms receiving biotech A rounds in the broader life science field (Fig. 1); the United Kingdom ranks a very distant second. Although relatively few biotechs in France and Switzerland received A rounds, companies in those countries pulled in more on average than companies in the United States (Table 2).
About this article
Nature Biotechnology (2017)
Human Molecular Genetics (2016)